Acknowledgement
Supported by : 식약청
References
- 식품의약품안전청. 임상시험 관련 순회교육. 임상시험 정책방향, 2011.
- 식품의약품안전청. 약사법 시행규칙 별표3의2 의약품임상시험관리기준, 2011.
- 식품의약품안전청 의약품본부 임상관리팀. 임상시험 이상반응보고 업무지침, 2007.
- ICH-GCP E2A. Guideline for Industry. Clinical Safety Data Management: Definitions and standards for Expedited Reporting.
- Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events [http://www.hhs.gov/ohrp/policy/advevntguid.html]
- U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs-Improving Human Subject Protection January 2009 Procedural.
- HY Shin. The suggestions for improving the institutional review board (IRB) in clinical trials: focusing on continuing management. J Korean Soc Clin Pharmacol Ther, 2011;19(1):5-13. (Korean) https://doi.org/10.1038/mt.2010.286